ArticleBiochemical genetics2026
Knockdown of Long Non-coding RNA-MALAT1 Ameliorates Diabetic Lower Limb Atherosclerotic Disease Through MiR-17-5p-Mediated Endothelial Cell Pyroptosis.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cellular and Molecular Mechanisms of Hyperglycemia-Induced Atherosclerosis and Intervention Strategies of Chinese Herbal Medicine.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We observed the expression of long non-coding RNA (lncRNA) MALAT1 and microRNA (miR)-17-5p in patients with diabetic lower extremity atherosclerosis (LEAD) and EA. hy926 human endothelial cells (EA. Hy926 cells). We further investigated whether knockdown of MALAT1 (sh-MALAT1) could protect endothelial cells and improve the occurrence of atherosclerosis through miR-17-5p, aiming to dissect the underlying mechanism. Patients with type 2 diabetes were stratified into two groups: those with lower extremity atherosclerotic lesions (LEAD group) and those without (T2DM group). For in vitro studies, EA. hy926 cell cultures were treated with high glucose concentrations and transfected. The mRNA expression levels of MALAT1 and miR-17-5p were accessed. The relationship between molecules was verified by double luciferase assay. Biological function was evaluated using lactate dehydrogenase (LDH) assay, Hoechst 33342/propidium iodide (PI) fluorescence staining, and Western blotting. MALAT1 was highly expressed and miR-17-5p was lowly expressed in both peripheral blood samples from LEAD patients and high glucose-cultured endothelial cells. Knockdown of MALAT1 (sh-MALAT1) or miR-17-5p mimic attenuated the release of LDH, the levels of pyroptosis-associated protein, and the number of PI-positive cells in high glucose-treated endothelial cells, while the miR-17-5p inhibitors had the opposite effect. The dual-luciferase assay determined that miR-17-5p is a downstream target of MALAT1. Finally, co-transfection with sh-MALAT1 and miR-17-5p inhibitors attenuated the protective effect of silenced MALAT1 on high glucose-mediated endothelial cell pyroptosis. MALAT1 may play an essential role in high glucose-induced endothelial cell pyroptosis by regulating miR-17-5p.
Indexed as
Identifiers
40947474What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.